Search

Background: The purpose of this study was to evaluate the efficacy and safety of fruquintinib‐based therapy as a salvage therapy for patients with advanced or metastatic sarcoma, including soft tissue sarcoma (STS) and bone sarcoma. Methods: Patients with advanced or metastatic sarcoma were divided into two groups. One group received fruquintinib monotherapy, while the other received fruquintinib combined therapy. Safety and efficacy of fruquintinib‐based therapy were recorded and reviewed retrospectively, including progression‐free survival (PFS), overall response rate (ORR), and adverse events (AEs). Results: Between August 2021 and December 2022, 38 sarcoma patients were retrospectively included. A total of 14 patients received fruquintinib alone (including 6 STS and 8 bone sarcoma), while 24 were treated with fruquintinib combined therapy (including 2 STS and 22 bone sarcoma). The median follow‐up was 10.2 months (95% CI, 6.4–11.5). For the entire population, the median PFS was 8.0 months (95% CI, 5.5–13.0). The ORR was 13.1%, while the disease control rate (DCR) was 86.8%. The univariate analysis showed that radiotherapy history (HR, 4.56; 95% CI, 1.70–12.24; p = 0.003), bone sarcoma (HR, 0.34; 95% CI, 0.14–0.87; p = 0.024), and treatment method of fruquintinib (HR, 0.36; 95% CI, 0.15–0.85; p = 0.021) were significantly associated with PFS. The multivariate analysis showed that patients without radiotherapy history were associated with a better PFS (HR, 3.71; 95% CI: 1.31–10.55; p = 0.014) than patients with radiotherapy history. Patients in combination group reported pneumothorax (8.3%), leukopenia (33.3%), thrombocytopenia (12.5%), diarrhea (4.2%), and anemia (4.2%) as the most frequent grade 3 or higher treatment‐emergent AEs (TEAEs), while there was no severe TEAEs occurred in the monotherapy group. Conclusions: Fruquintinib‐based therapy displayed an optimal tumor control and an acceptable safety profile in patients with advanced or metastatic sarcoma. [ABSTRACT FROM AUTHOR]

To investigate the influence of the wind attack on a bridge deck's flutter performance, the concept of "pressure flutter derivatives" was introduced as a part of the "distributed aerodynamic characteristics" method, which can be used to visualize the dominant fluctuations of the pressure field. The distributions of the aerodynamic damping and stiffness under different wind attack angles were visualized, instead of using an overall force perspective. The analysis was carried out through two-dimensional computational fluid dynamics simulations based on a typical box deck section. Necessary data were obtained through the forced vibrations of the deck. The dominant pressure fluctuations were demonstrated, around which the wind attack angles' impact on the Scanlan flutter derivatives was discussed. For the deck section used in this study, the wind attack angle was found to most affect the windward parts of the deck. When wind attack angle ranged from − 1.5 ° to 3 ° , two regions contributed the most: one located behind the windward faring vertex and the other located behind the first vertex of the upper slab. When the wind attack angle decreased to − 3 ° , a new dominant region appeared behind the first vertex of the lower slab, which caused a sudden reduction of the flutter critical speed. [ABSTRACT FROM AUTHOR]

In recent years, interest has been growing in the stability control of cylindrical structures in a flow field using full/partial coatings of porous media. However, the partial application of porous coatings to arrays of cylinders with rough surfaces has rarely been studied. This paper numerically investigates the passive flow control of an array of rough cylinders partially coated with porous media on their leeward side in the subcritical flow regime (Re = 3900). This is achieved through two-dimensional direct numerical simulations and the Cartesian cut-cell method, which facilitate flow simulations around complex porous media and rough surfaces in an accurate and flexible manner. In contrast to macroscopic models, this study employs a quasi-microscopic model to simplify the porous structure for each cylinder, providing an accurate and intuitive means of describing the inflow details of porous media near the central cylinder. The porosities and pores per inch of the porous media are defined in terms of the alignment angles and radii. Similarly, the surface roughness of a cylinder is simulated by the attachment of small circular appendages. The accuracy and capacity of the presented numerical approach are demonstrated via a numerical case study with a single smooth cylinder. The influence of the porous media on the flows around a single rough cylinder and an array of rough cylinders is thoroughly investigated and discussed. [ABSTRACT FROM AUTHOR]

Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-23-516/coif). The authors have no conflicts of interest to declare.

Purpose: We investigated the safety and preliminary efficacy of anti-PD-L1 antibody (ZKAB001) as maintenance therapy for localized patients with high-grade osteosarcoma to reduce the risk of recurrence and metastasis., Patients and Methods: This open-label Phase I/II study was divided into dose-escalation Phase I and expansion Phase II. Phase I used a 3+3 design with ZKAB001 at three escalating doses ranging: 5, 10, 15 mg/kg every 2 weeks in 9 patients with localized high-grade osteosarcoma and Phase II tested 10 mg/kg in 12 patients for up to 24 cycles. Primary endpoints were safety and tolerability assessed using CTCAE4.0.3., Results: Between October 2018 and 2019, 21 eligible patients were enrolled and accepted ZKAB001 treatment: 9 in the dose-escalation phase, and 12 in expansion phase. Six patients with disease progression withdrew from this study and follow-up is ongoing. The MTD was not defined in Phase I. All doses had a manageable safety profile. The recommended dose in Phase II was set at 10 mg/kg. Most frequent immune-related adverse events were thyroiditis (76.2%) and dermatitis (42.9%). Only 1 (4.8%) of 21 patients had a Grade 3 skin rash. The median 3-year event-free survival (EFS) and overall survival (OS) were not established; however, 24-month EFS was 71.4% (95% confidence interval, 47.2-86.0) and 2-year OS was 100%. Preliminary efficacy data showed EFS benefits in patients with PD-L1 positive or an MSI-H sub-population., Conclusions: Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized patients with osteosarcoma., (©2022 American Association for Cancer Research.)